A 24-year-old man presents to the ambulatory clinic after noticing a painless lump in his right scrotum during a shower three days ago. He reports no local trauma, dysuria, urethral discharge, or systemic symptoms such as weight loss or night sweats. He has no significant past medical history. Vital signs are within normal limits. Physical examination reveals a 2.5-cm, firm, non-tender nodule palpable on the anterolateral aspect of the right testicle. The mass does not transilluminate. There is no inguinal lymphadenopathy, and the contralateral testicle is normal. Which of the following tests represent the most appropriate immediate next steps in the diagnostic workup? (Select exactly two options)
- Bilateral scrotal ultrasonographyCevap
- Serum alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase levelsCevap
- CComputed tomography of the abdomen and pelvis
- DPercutaneous core needle biopsy of the testicular mass
- EEmpiric trial of targeted antibiotic therapy
Cevap
The most appropriate immediate next steps in the diagnostic workup are bilateral scrotal ultrasonography and measurement of serum tumor markers (alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase).
Bilateral scrotal ultrasonography is the standard, most cost-effective initial imaging modality to characterize a scrotal mass, distinguishing between benign cystic fluid collections and solid intra-testicular lesions concerning for cancer. Concurrently, obtaining serum tumor markers (alpha-fetoprotein, beta-human chorionic gonadotropin, and lactate dehydrogenase) is required as an immediate next step before any surgical intervention occurs. These markers establish a critical baseline, as their rate of decline post-orchiectomy and their absolute values are highly prognostic and guide further staging and adjuvant therapy decisions.
Adım Adım Çözüm
Anahtar Kavram
The initial diagnostic sequence for a suspected testicular malignancy requires scrotal ultrasonography to characterize the mass and baseline serum tumor markers (AFP, beta-hCG, LDH) for prognosis, while strictly avoiding percutaneous biopsy to prevent tumor seeding.